Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma

Table 3 Univariate analyses

Clinicopathological data					Surgical data
	Category	n	MST (m)	P value		Category	n	MST (m)	P value
Age (yr)	≥ 60	18	17.9	0.9267	Anatomical hepatectomy	-	3	39.0	0.2162
	< 60	12	29.7			+	27	16.9
Sex	Male	28	17.9	0.1584	Operation time (min)	< 340	15	28.4	0.4177
	Female	2	-			≥ 340	15	14.8
HBV/HCV	-	6	15.0	0.2674	Blood loss (mL)	< 690	15	29.7	0.6355
	+	24	29.7			≥ 690	15	16.4
Alb (g/dL)	≥ 3.7	15	33.5	0.3444	Number of tumors in the remnant liver	1-3	12	56.5	0.0283a
	< 3.7	15	17.4			≥ 4	18	14.8
T-Bil (mg/dL)	≤ 0.8	19	28.4	0.5131	POCR	+	8	56.6	0.0041a
	> 0.8	11	16.5			-	22	14.8
PT (%)	≥ 90	17	17.9	0.7839
	< 90	13	28.4
ICGR15 (%)	≥ 15	12	29.7	0.6790
	< 15	18	16.5
AFP (ng/mL)	< 200	16	29.7	0.5569
	≥ 200	14	17.9
PIVKA-II (AU/mL)	< 100	3	73.2	0.0584
	≥ 100	27	16.9
Child-pugh class	A	27	29.7	< 0.0001
	B	3	6.4
Tumor size (cm)	≥ 10 cm	15	12.2	0.0485
	< 10 cm	15	29.7
Differentiation	wel/mod	17	17.9	0.5449
	por	13	28.4
pN	-	28	17.9	0.2335
	+	2	56.5
Macrovascular invasion	-	5	9.5	0.0053
	+	25	30.0
BCLC stage	B	12	33.8	0.7652
	C	18	16.9
Distant metastasis	-	27	28.4	0.6013
	+	3	12.1

^aP < 0.05. MST: Mean survival time; PT: Prothrombin time; ICGR15: Indocyanine green retention rate at 15 min; AFP: Alpha-fetoprotein; PIVKA-II: Protein induced by vitamin K absence/antagonist-II; BCLC: Barcelona Clinic Liver Cancer.